Avihu Tamir of Kanabo & Asaf Sella of Medocann discuss their new development & distribution partnership

Justin Waite
Vox Markets Podcast
09:28, 7th October 2021

AudioBoom Player

If you find this podcast useful please give it a rating and review on iTunes by clicking here


Avihu Tamir of Kanabo & Asaf Sella, CEO Medocann discuss their new development & distribution partnership

Avihu Tamir of Kanabo Group #KNB FOLLOW & Asaf Sella, CEO Medocann discuss their new partnership for the development of unique new products with exclusive distribution rights into the German and UK medical cannabis markets.

Highlights

The partnership agreement between Kanabo and Medocann will focus on the co-development of new and novel strains from flowers and extracts made for specific medical indications through the combination of Kanabo's preclinical data on the effect of cannabis on different illnesses and Medocann's genetics bank, breeding and strain development expertise. The new strains and extracts will be used to launch new co-developed medical cannabis products ("Co-Developed Products").

The agreement includes the exclusive rights to distribute the Co-Developed Products into both the UK and German medical cannabis markets. The agreement stipulates that Medocann and Kanabo will use commercially reasonable efforts to have the Co-Developed Products available for sale in the target markets, based on 1,000kg of cannabis raw material over the first three years of the agreement, conditional on the existence of all required import and export regulatory documents.

The price at which Co-Branded Products will be sold, which will in any event be at least the then-current premium market price, which as of the date of the agreement is estimated at EUR 9.00 (Nine Euros) per gram.

About Kanabo

Kanabo Group Plc is an R&D company currently selling a range of THC-Free Retail CBD Products in the Primary Markets and is in the process of developing further Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
Login or register to post comments

Recent Articles
Watchlist